Seizures and hepatotoxicity following sulphasalazine administration.
Sulphasalazine (SSZ) is a widely used second-line agent for several rheumatic diseases. Most of its side effects are relatively minor and dose dependent. We report a patient with juvenile onset chronic arthritis who developed hepatotoxicity and seizures on the third week of SSZ when the daily dose was increased to 2 g. Clinical and laboratory findings of liver and central nervous system toxicity gradually returned to normal in the month following SSZ withdrawal.
Sentürk
T
T
Department of Immunology, Medical School of Ankara University, Turkey.
Aydintuğ
A O
AO
Düzgün
N
N
Tokgöz
G
G
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008099:Liver / Q000503:physiopathology*; D008107:Liver Diseases / Q000503:physiopathology; D012640:Seizures / Q000139:chemically induced* / Q000503:physiopathology; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
D018501:Antirheumatic Agents; D012460:Sulfasalazine